Pay in 4 interest-free payments of $8.00 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
LX-7101 also displays potent inhibition of Akt1 with an IC50 of less than 1 nM
These effects can be recapitulated by (R)-2-HG
PubMed Central PMCID: PMC2731875
InChiKey: GAJWNIKZLYZYSY-OKUPSQOASA-N
VX 765 - CAS# 273404-37-8 282 LX-7101 also displays potent inhibitionVX 765, CAS No. 273404 37 8, is designed to inhibit Caspase, which is an enzyme that controls the generation of two cytokines, IL 1b and IL 18. VX 765 has been shown to inhibit acute seizures in preclinical models. In addition, VX 765 has shown activity in preclinical models of chronic epilepsy. VX 765 had been dosed in over 100 patients in phase I and phase IIa clinical trials relating to other diseases, including a 28 day phase IIa clinical trial in
US$ 1995.36
US$ 2463.51
US$ 3653.34